The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction

Description

Caloric restriction (and RYGB) improves insulin action and lowers fasting glucose, glucagon and EGP, without changes in postprandial EGP and glucagon concentrations. Caloric restriction also improves hepatic steatosis and lowers fasting AA. These changes may represent restoration of glucagon's hepatic actions. This experiment will determine whether caloric restriction improves glucagon's actions on hepatic amino acid, carbohydrate and lipid metabolism in T2DM in comparison to a baseline experiment performed separately in people with T2DM.

Conditions

Type2diabetes

Study Overview

Study Details

Study overview

Caloric restriction (and RYGB) improves insulin action and lowers fasting glucose, glucagon and EGP, without changes in postprandial EGP and glucagon concentrations. Caloric restriction also improves hepatic steatosis and lowers fasting AA. These changes may represent restoration of glucagon's hepatic actions. This experiment will determine whether caloric restriction improves glucagon's actions on hepatic amino acid, carbohydrate and lipid metabolism in T2DM in comparison to a baseline experiment performed separately in people with T2DM.

The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction

The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction

Condition
Type2diabetes
Intervention / Treatment

-

Contacts and Locations

Rochester

Mayo Clinic in Rochester, Rochester, Minnesota, United States, 55905

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * We will recruit up to 20 weight-stable, subjects with type 2 diabetes
  • * BMI ≥ 28 Kg/M2
  • * Diabetes is managed by diet alone or a combination of oral agents
  • * History of prior upper abdominal surgery e.g. gastric banding, pyloroplasty, vagotomy.
  • * Active systemic illness or malignancy.
  • * Symptomatic macrovascular or microvascular disease.
  • * Contraindications to MRI (e.g. metal implants, claustrophobia).
  • * Hematocrit \< 35%
  • * TSH \< 0.4 or \> 5.5.
  • * Consumption of \> 2 alcohol drinks per day or \> 14 per week or a positive AUDIT questionnaire.

Ages Eligible for Study

25 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Adrian Vella,

Adrian Vella, PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

2026-12-31